제품 수집
제품 세부정보
Source
Chimeric Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) is recombinantly expressed in HEK293. It consists of rabbit variable regions genetically fused to rabbit IgG constant domains.
Antibody Type
Recombinant Monoclonal
Clone
1M2C3
Isotype
Rabbit IgG, Kappa
Host Species
Rabbit
Immunogen
Doxorubicin-BSA
Specificity
Specifically recognizes Doxorubicin.
Application
ApplicationRecommended Use / PerformanceELISA0.2-2 μg/mLPurification
Protein A purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
Bioactivity-ELISA
Immobilized Doxorubicin-ADC at 0.1 μg/mL (100 μL/well) can bind Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) (Cat. No. DON-MY2216) with a linear range of 0.06-8 ng/mL (QC tested).
Protocol
Serial dilutions of Doxorubicin were added into Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) (Cat. No. DON-MY2216): Doxorubicin-ADC binding reactions. The half maximal inhibitory concentration (IC50) is 0.009186 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) (Cat. No. DON-MY2216) with Doxorubicin-ADC, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecan and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) (Cat. No. DON-MY2216), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Doxorubicin-ADC, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecan and Trastuzumab-DM1 conjugated antibodies used at 0.25 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) (Cat. No. DON-MY2216) is specific to Doxorubicin-ADC and has no cross-reactivity with IgG1-MMAF, Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecan and Trastuzumab-DM1 (Routinely tested).
사용자 리뷰 댓글 남기기
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
배경 소개
프론티어 진행
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
